Genome editing and cancer: How far has research moved forward on CRISPR/Cas9?
Saikat Mitra, Joyatry Sarker, Anik Mojumder, Tasmim Bintae Shibbir, Rajib Das, Talha Bin Emran, Trina Ekawati Tallei, Firzan Nainu, Asma M. Alshahrani, Kumarappan Chidambaram, Jesús Simal‐Gándara
Abstract
Cancer accounted for almost ten million deaths worldwide in 2020. Metastasis, characterized by cancer cell invasion to other parts of the body, is the main cause of cancer morbidity and mortality. Therefore, understanding the molecular mechanisms of tumor formation and discovery of potential drug targets are of great importance. Gene editing techniques can be used to find novel drug targets and study molecular mechanisms. In this review, we describe how popular gene-editing methods such as CRISPR/Cas9, TALEN and ZFNs work, and, by comparing them, we demonstrate that CRISPR/Cas9 has superior efficiency and precision. We further provide an overview of the recent applications of CRISPR/Cas9 to cancer research, focusing on the most common cancers such as breast cancer, lung cancer, colorectal cancer, and prostate cancer. We describe how these applications will shape future research and treatment of cancer, and propose new ways to overcome current challenges.